A trial looking at everolimus and pasireotide for neuroendocrine tumours of the lung or thymus (LUNA)

This trial is looking at using either everolimus (Afinitor) or pasireotide alone, or both together, for people with neuroendocrine tumour (NET) of the lung or thymus.

Neuroendocrine tumours (NETs) are a rare group of cancers that make and release hormones. This trial is for people who have NET that started in the lung or the thymus gland.

Doctors often use drugs called somatostatin analogues to help control the symptoms of NETs. Research suggests that these drugs may also help stop NETs growing. Pasireotide is a new type of somatostatin analogue.

Everolimus is a biological therapy. It stops signals that cancer cells use to divide and grow. We know from research that everolimus may be useful to treat NETs.

This trial is comparing everolimus and pasireotide together with either everolimus or pasireotide alone. The aim of the trial is to find out which is best at shrinking or slowing down the growth of neuroendocrine tumours of the lung or thymus.